The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.
The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.
<iframe src="https://hindustansphere.com/embed/cluster/cc5b749853138a58ce0062d15c5ace441dbb743e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know"></iframe>
The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.
